



AGENDA

Utah Department of Health
Pharmacy and Therapeutics Committee

Thursday, November 17, 2016
7:15 a.m. to 8:45 a.m.
Cannon Health Building
Room 128

Persons who wish to address the P&T Committee may contact Bryan S. Larson at (bslarson@utah.gov) prior to the meeting, or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints.

- 1) Call to orderClinton Sheffield, MD, Chair
 - a) Announce Quorum
- 2) Welcome and IntroductionsClinton Sheffield, MD, Chair
 - a) Review and Approval of Minutes
 - b) Housekeeping
- 3) DUR Board UpdateRobyn Seely, PharmD
- 4) November Reviews
 - a) Anti-Anxiety BenzodiazepinesMelissa Archer, PharmD
 - i) Acetazolamide, Carbamazepine, Ethosuximide, Ethotoin, Methsuximide, Pentobarbital, Phenobarbital, Phenytoin, Primidone, Valproic Acid (and derivatives)
 - b) Older Anticonvulsant Agents.....Vicki Frydrych, PharmD
 - i) Acetazolamide, Carbamazepine, Ethosuximide, Ethotoin, Methsuximide, Pentobarbital, Phenobarbital, Phenytoin, Primidone, Valproic Acid (and derivatives)
 - c) Public Comment
 - i)
 - d) Other States Report Bryan S. Larson, PharmD
 - e) Committee Discussion/Questions
 - f) Committee Action
- 5) Next Meeting January 19, 2017 (Opioid Combination Products) – No December Meeting
- 6) AdjournedClinton Sheffield, MD, Chair

The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to:

Dr. Joanne LaFleur
 College of Pharmacy
 30 South 2000 East
 SLC, UT 84112-5820

All materials must be clearly labeled that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

Tentative 2017 Pharmacy & Therapeutics Committee Schedule

Month	Topic	Agents
15 Dec 2016*	No Meeting	N/A
19 Jan 2017*	Opioid-Combination Products	Acetaminophen/Codeine, Acetaminophen/Tramadol, Acetaminophen/Caffeine/Codeine, Acetaminophen/Caffeine/Dihydrocodeine, Acetaminophen/Codeine/Butalbital/Caffeine, Acetaminophen/Codeine/Doxylamine, Acetaminophen/Hydrocodone, Acetaminophen/Oxycodone, Acetaminophen/Pentazocine, Aspirin/Caffeine/Dihydrocodeine, Aspirin/Codeine/Carisoprodol, Aspirin/Oxycodone (Percodan 1989), Butalbital Compound/Codeine, Ibuprofen/Hydrocodone, Ibuprofen/Oxycodone
16 Feb 2017*	HIV – Non-Nucleoside Reverse Transcriptase Inhibitors	Delavirdine, Efavirenz, Etravirine, Nevirapine, Rilpivirine
	HIV –Nucleoside Reverse Transcriptase Inhibitors	Abacavir, Didanosine, Emtricitabine, Lamivudine, Stavudine, Zidovudine
16 Mar 2017*	HIV – Integrase Inhibitors	Dolutegravir, Elvitegravir, Raltegravir
	HIV – Entry Inhibitors	Enfuvirtide, Maraviroc
20 Apr 2017*	HIV – Nucleotide Reverse Transcriptase Inhibitors	Tenofovir
	HIV – Combination Products	Abacavir / Dolutegravir / Lamivudine Abacavir / Lamivudine Abacavir / Lamivudine / Zidovudine Atazanavir / Cobicistat Darunavir / Cobicistat Efavirenz / Emtricitabine / Tenofovir Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Emtricitabine / Rilpivirine / Tenofovir Emtricitabine / Rilpivirine / Tenofovir Alafenamide Emtricitabine / Tenofovir Emtricitabine / Tenofovir Alafenamide Lamivudine / Zidovudine Lopinavir / Ritonavir
18 May 2017*	Anti-Gout Agents	Allopurinol, Colchicine, Colchicine & Probenecid, Febuxostat, Lesinurad
15 Jun 2017*	Parathyroid Hormone Analogs	Teriparatide, Parathyroid Hormone
20 Jul 2017*	Long-Acting Anticholinergic, Beta-2 Agonist Combination Inhalers	Glycopyrrolate/Formoterol, Umeclidinium/Vilanterol, Tiotropium/Olodaterol, Indacaterol/Glycopyrrolate

*Please note: all topics are tentative and subject to change.

Individuals with questions about accessibility or requesting special accommodations for this meeting should contact Bryan S. Larson at bslarson@utah.gov or (801) 538-6079.